2026 Global: Antibiotics In Animal Feed-Competitive Review (2032) report
Description
The 2026 Global: Antibiotics In Animal Feed-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antibiotics in animal feed by geography and historical trend. The scope of the report extends to sizing of the antibiotics in animal feed market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Zoetis leads the major companies in antibiotics for animal feed, generating US$8.5 billion in 2023 revenues from vaccines, pharmaceuticals, and treatments for livestock and companion animals, including antibiotic solutions for disease prevention. Boehringer Ingelheim follows with US$4.7 billion, specializing in antibiotics targeting respiratory, infectious, and reproductive disorders in livestock and poultry. Merck Animal Health (MSD) ranks third at US$5.6 billion, driven by demand for poultry, swine, and ruminant antibiotics despite market fluctuations. Elanco, Phibro Animal Health, and Virbac complete the top six, offering broad-spectrum antibiotics integrated into feed for growth promotion and infection control in pigs, cattle, and birds. These firms dominate due to extensive R&D and global distribution, addressing regulatory pressures on antibiotic use.
Ceva Santé Animale, Dechra Pharmaceuticals, Huvepharma, and Vetoquinol form the next tier, with Vetoquinol reporting US$571 million from antibiotics in feed for cattle, pigs, and pets, focusing on anti-parasite and internal medicine applications. Huvepharma and Ceva emphasize affordable, feed-grade antibiotics for poultry and swine, enhancing nutrient absorption and immunity amid bans on growth promoters in regions like the EU. Dechra targets companion and farm animals with specialized formulations, while Phibro innovates in medicated feeds to combat resistance. Market concentration highlights these players' 70-80% share, fueled by rising livestock demand in Asia and Latin America.
Regulatory shifts favor reduced antibiotic reliance, yet these ten—Zoetis, Boehringer Ingelheim, Merck, Elanco, Phibro, Virbac, Ceva, Dechra, Huvepharma, and Vetoquinol—persist through precision dosing and alternatives integration. Innovations like Zoetis's parasiticides and Boehringer's vaccines complement feed antibiotics, sustaining revenues amid sustainability demands. Global operations span over 100 countries, with Asia-Pacific growth at 7% CAGR, positioning them against competitors like DSM in probiotics. Their portfolios ensure animal productivity, supporting a US$40 billion veterinary antibiotics sector.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antibiotics in animal feed by geography and historical trend. The scope of the report extends to sizing of the antibiotics in animal feed market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Zoetis leads the major companies in antibiotics for animal feed, generating US$8.5 billion in 2023 revenues from vaccines, pharmaceuticals, and treatments for livestock and companion animals, including antibiotic solutions for disease prevention. Boehringer Ingelheim follows with US$4.7 billion, specializing in antibiotics targeting respiratory, infectious, and reproductive disorders in livestock and poultry. Merck Animal Health (MSD) ranks third at US$5.6 billion, driven by demand for poultry, swine, and ruminant antibiotics despite market fluctuations. Elanco, Phibro Animal Health, and Virbac complete the top six, offering broad-spectrum antibiotics integrated into feed for growth promotion and infection control in pigs, cattle, and birds. These firms dominate due to extensive R&D and global distribution, addressing regulatory pressures on antibiotic use.
Ceva Santé Animale, Dechra Pharmaceuticals, Huvepharma, and Vetoquinol form the next tier, with Vetoquinol reporting US$571 million from antibiotics in feed for cattle, pigs, and pets, focusing on anti-parasite and internal medicine applications. Huvepharma and Ceva emphasize affordable, feed-grade antibiotics for poultry and swine, enhancing nutrient absorption and immunity amid bans on growth promoters in regions like the EU. Dechra targets companion and farm animals with specialized formulations, while Phibro innovates in medicated feeds to combat resistance. Market concentration highlights these players' 70-80% share, fueled by rising livestock demand in Asia and Latin America.
Regulatory shifts favor reduced antibiotic reliance, yet these ten—Zoetis, Boehringer Ingelheim, Merck, Elanco, Phibro, Virbac, Ceva, Dechra, Huvepharma, and Vetoquinol—persist through precision dosing and alternatives integration. Innovations like Zoetis's parasiticides and Boehringer's vaccines complement feed antibiotics, sustaining revenues amid sustainability demands. Global operations span over 100 countries, with Asia-Pacific growth at 7% CAGR, positioning them against competitors like DSM in probiotics. Their portfolios ensure animal productivity, supporting a US$40 billion veterinary antibiotics sector.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
